

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



Eur pâisches Patentamt
 European Patent Office
 Office européen des brevets

(11) Publication number:

0 114 333
 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 83112757.6

(51) Int. Cl.³: A 61 K 37/02
 A 61 K 31/40, C 07 C 103/52

(22) Date of filing: 19.12.83

(30) Priority: 27.12.82 US 453257

(71) Applicant: SCHERING CORPORATION
 2000 Galloping Hill Road
 Kenilworth, New Jersey 07033(US)

(43) Date of publication of application:
 01.08.84 Bulletin 84/31


(72) Inventor: Watkins, Robert Wayne
 154 Davey Street
 Bloomfield New Jersey 07003(US)

(84) Designated Contracting States:
 AT BE CH DE FR GB IT LI NL SE

(74) Representative: Antony, Fritz, Dr. et al,
 P.O. Box 601 Winkelriedstrasse 35
 CH-6002 Lucerne(CH)

(54) Pharmaceutical composition.

(57) Topical ophthalmologically acceptable composition useful for reducing and controlling the elevated intraocular pressure associated with glaucoma which comprises an angiotensin converting enzyme (ACE) inhibitor in combination with an ophthalmologically acceptable carrier. Preferred compositions contain captopril or an ACE inhibitor of formula



R_2 is alkyl, benzyl, benzylthio, benzyloxy, phenylthio or phenoxy;

R_1 , R_3 , R_4 and R_6 are hydrogen or alkyl;


R_5 is hydrogen, alkyl or amino alkyl;

p is 0, 1 or 2;

q is 0, 1 or 2, provided that the sum of p and q is 1 or 2 and that p is not 0 in formula Z;

r is 1 or 2.

wherein A is



EP 0 114 333 A2

- 1 -

PHARMACEUTICAL COMPOSITION

Glaucoma is an ocular disease complex associated with an elevated pressure within the eye (i.e., intraocular pressure, IOP). As a result of the elevated IOP, 5 damage to the optic nerve head resulting in irreversible loss of visual function may ensue. Untreated, this condition may eventually lead to blindness.

Ocular hypertension, i.e., the condition of elevated intraocular pressure without optic nerve head 10 damage or characteristic glaucomatous visual field loss, is now believed by the majority of ophthalmologists to represent the earliest phase in the onset of glaucoma.

A number of the drugs presently employed to treat glaucoma are not entirely satisfactory, particularly 15 in the earliest course of the disease when the side effects they produce are often worse than the symptoms of the disease.


Epinephrine used as a topical solution, must be utilized cautiously in patients with high blood pressure, 20 diabetes, hyperthyroidism and cerebral arteriosclerosis due to the possibility of systemic action.

Timolol, a clinically utilized, topically applied agent for lowering intraocular pressure, must be used with caution in patients in whom beta-adrenergic blockade may be undesirable. Systemic absorption of 5 topically administered timolol and systemic beta-blockade are responsible for the contraindication of timolol therapy for glaucoma in patients with compromised pulmonary function.

Pilocarpine, a topical drug, although 10 considered systemically harmless and quite effective, may cause considerable local difficulties. Pupil constriction may cause the eye to lose its ability to adapt from light to dark. Accommodation may become stimulated so that the patient's refraction is sometimes 15 incorrect and vision becomes blurred. The drug itself may cause a local vasodilation and red eyes. Irritation is common.


Carbonic anhydrase inhibitors have been used systemically but they have a number of disadvantages. 20 While effective in lowering intraocular pressure, they often cause a numbness and tingling, gastrointestinal upsets and, frequently, depression, lethargy, a loss of appetite, and general malaise. European Patent Application 81400326.5, Publication number 36,351 25 attempts to overcome these difficulties by the topical administration of an alkali metal salt of a carbonic anhydrase inhibitor.

The present invention provides a pharmaceutical composition for reducing and controlling the 30 elevated intraocular pressure associated with glaucoma.







The invention sought to be patented in its pharmaceutical composition aspect is a topical ophthalmologically acceptable composition useful for reducing and controlling the elevated intraocular pressure associated with glaucoma which comprises an intraocular pressure reducing effective amount of a pharmaceutically acceptable angiotensin converting enzyme (ACE) inhibitor in combination with an ophthalmologically acceptable carrier for topical use. The composition may contain one or more additional therapeutic agents.

In a preferred composition according to this invention said ACE inhibitor is a compound having the structural formula



wherein A is



R₂ is alkyl having from 1 to 6 carbon atoms, benzyl, benzylthio, benzyloxy, phenylthio or phenoxy;



R₁, R₃, R₄, and R₆ are the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms;

R₅ is hydrogen, alkyl having from 1 to 6 carbon atoms or amino alkyl having from 1 to 6 carbon atoms;

p is 0, 1 or 2;
 10 q is 0, 1 or 2, provided that the sum of p and q is 1 or 2 and that p is not 0 in formula 2; r is 1 or 2; and the pharmaceutically acceptable salts thereof.


15 Preferably in formula I R₁ and/or R₄ and/or R₆ is hydrogen and/or R₂ is benzyl and/or R₅ is methyl and/or p and/or q and/or r are 1. Preferably A is the group X, Y or Z. Preferably the compounds are of the S,S,S-configuration.

20 Preferred compositions of the invention comprise ACE inhibitors having the following structural formulae:




0114339


- 4a -



IV



V



In the above formulae the heavy line (→) utilized at the chiral centers means that the substituent so bonded is projected above the plane of the paper. The configuration at these chiral centers is 5 denoted as "S". The substituent R₃ may be hydrogen or alkyl having from 1 to 6 carbon atoms. R₃ is preferably hydrogen or ethyl.

The invention sought to be patented in its pharmaceutical method aspect is a method for reducing and 10 controlling the elevated intraocular pressure associated with glaucoma in a human which method comprises administering to said human an effective amount of the above-defined pharmaceutical composition.

The compounds utilized in the topical ophthalmologically acceptable pharmaceutical compositions and 15 methods of the invention are known in the art as angiotensin converting enzyme (ACE) inhibitors. Angiotensin II, a pressor substance, is produced in vivo by the action of angiotensin converting enzyme (ACE) on 20 angiotensin I. Compounds capable of inhibiting the action of ACE are clinically useful for controlling the blood pressure of humans suffering from hypertension. For example, captopril, Compound II is currently in clinical use for this purpose. Other ACE inhibitors are 25 known in the art, and may have a variety of structures. See, for example, An. Rev. Biochem., 51, 283(1982) and references cited therein.

described by Cushman and Cheung, Biochem. Pharmacol., 20,
1637(1971). The ACE used is prepared in a manner similar
to that of Cheung and Cushman, Biochem. Biophys. Acta.,
293, 451(1973). Incubation for ACE assays is carried out
15 at 37°C. Each 0.25 ml assay mixture contains the
following components: 100 mM of potassium phosphate
buffer containing 300 mM sodium chloride, 5 mM HHL and
1.87 mU enzyme at pH 8.3 and various concentrations of
inhibitors. The enzyme reaction is terminated after 60
20 minutes by the addition of 0.25 ml of 1N HCl. Inhibitors
are dissolved in appropriate solvents. Hippuric acid
solution for a standard curve is prepared in a similar
manner.

Each experiment involves replicate incubations
25 for each condition to be studied. IC₅₀ values (the
concentration required for the 50% inhibition of ACE
activity) are derived from calculated regression lines.
Each experiment utilizes multiple concentrations of
inhibitor.

Many ACE inhibitors are known in the art and may be prepared by known methods or by variations thereof. For example, the compound having structural formula II may be prepared as described in United States Patent 5 4,046,889; the compounds having structural formulae III and IV may be prepared as described in European Patent Application 81108348.4, publication number 50,800.

The compositions of this invention are considered to be no more toxic than compositions containing the ACE inhibitors for controlling hypertension.

10 When topically administered to the eye, the compounds of the invention reduce intraocular pressure (IOP). For example, compound II caused falls in IOP of a magnitude similar to those produced by the anti-glaucoma agent timolol when each were administered at 15 concentrations of 0.25, 0.5, 1.0 and 2.0 (w/v%) and tested by the following procedure:

Male New Zealand white rabbits having a normal IOP are conditioned to the laboratory setting for at least one 4 hr period before being used to study drug 20 effects. A Makay-Marg applanation tonometer is used to measure IOP. Readings, in mm Hg, are taken in triplicate and the average is recorded.

Rabbits are restrained in a cloth sack 2 min. prior to IOP determination. The left lower eyelid is 25 retracted to form a pouch and 1 drop of a local anesthetic is irrigated over the cornea. The lower eyelid is then held closed over the eye for about 1 min. Corneal anesthesia is repeated before each set of IOP determinations. Readings are taken just before dosing 30 with drug (0 time) and at hourly intervals thereafter. Drugs are administered in a 50 ul volume in the same manner as the anesthetic.

Summary of test results:

observation time : 4 hours

pretreatment intraocular pressure: 19.6-21.4 mmHg

	compound	concentration %	maximum decrease [mmHg]
5	Timolol	0.25	-1.7 ± 0.6
		0.5	-2.4 ± 0.8
		1.0	-4.4 ± 0.4
		2.0	-3.6 ± 0.7
10	Captopril	0.25	-2.4 ± 0.5
		0.5	-2.4 ± 0.8
		1.0	-3.7 ± 0.6
		2.0	-4.1 ± 0.6
15	I	0.1	-3.7 ± 0.9
		0.25	-2.1 ± 0.7
		0.5	-3.4 ± 1.1
		1.0	-3.2 ± 0.7
20	II	0.25	-3.5 ± 0.6
		0.5	-1.2 ± 0.7
		1.0	-2.7 ± 1.1

I: N-[1-(S)-Carboxy-3-phenylpropyl]-(S)-alanyl-(S)-proline

II: 1-{N-[1(S)-Carboxy-3-phenylpropyl]-(S)-alanyl}-cis,syn-octahydroindole-2(S)-carboxylic acid

The active compounds of the invention (ACE inhibitors) are administered in the form of ophthalmic pharmaceutical compositions adapted for topical administration to the eye; such as solutions, suspensions, 5 ointments and solid inserts. Formulations of these compounds may contain from 0.01 to 5% and especially 0.25% to 2% of medicament. Other concentrations may be employed provided the dose is effective in lowering intraocular pressure. As a unit dosage form, between 10 0.01 to 2.5 mg., preferably 0.05 to 2.5 mg., and especially 0.1 to 1.0 mg. of the active compound is applied to the human eye, generally on a daily basis. Individual dosage requirements are variable; however, and must be administered on the basis of the severity of the 15 disease and the response of the patient.

To prepare suitable dosage forms, the active compounds may be conveniently admixed with a non-toxic pharmaceutically acceptable carrier suitable for topical ophthalmologic administration. Typical of such pharmaceutically acceptable carriers are, for example, 20 water, mixtures of water and watermiscible solvents such as lower alkanols or vegetable oils, petroleum based jelly, and including also from 0.5 to 5% by weight of hydroxyethyl cellulose, ethyl oleate, carboxymethyl cellulose, polyvinylpyrrolidone, and other water soluble 25 ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methyl cellulose, alkali metal carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose; acrylates such as polyacrylic acids salts, ethylacrylates; polyacrylamides; natural products such as gelatin, alginates, pectins, tragacanth, karaya, chondrus, agar, acacia; the starch derivatives such as 30

15 phenyl ethanol; buffering ingredients such as alkali metal chloride, borate, acetate, gluconate buffers; antioxidants such as sodium metabisulfite, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and the like; and other conventional ingredients such as
20 sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitate, dioctyl alkali metal sulfosuccinate, monothioglycerol, ethylenediamine tetracetic acid and the like.

Additionally, suitable ophthalmic vehicles can
25 be used as carrier media for the present purpose including conventional phosphate buffer vehicle systems, isotonic boric acid vehicles, isotonic alkali chloride vehicles, tris and the like.

The pharmaceutical preparation may also be
30 in the form of a solid insert. For example, one may use a solid water soluble polymer as the carrier for the medicament. Inserts that are known in the art that are suitable for this use include those described in British

- 10 -

Patent 15611, and in United States Patents 3,993,071; 3,986,510; 3,868,445; and 3,867,510. Solid water insoluble inserts, such as those prepared from ethylene vinyl acetate copolymer, may also be utilized.

- 5 The compositions of the invention may include additional therapeutic agents in addition to the ACE inhibitor. For example antibiotics, anesthetics as well as other IOP lowering agents may be present.
-

In the following formulation examples A and B stand for the active ingredients:

A: 1-{N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl}-cis,syn-octahydroindole-2(S)-carboxylic acid

5

B: 7-{N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl}-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid

*stands for the concentration of the active ingredient

10 which is as follows:

	<u>active ingredient</u>	
	A	B
Example 1	10	8 [mg/ml]
Example 2	12	18 [mg/ml]
15 Example 3	20	15 [mg/g]
Example 4	15	25 [mg/g]
Example 5	5	[mg/ml]

The formulations are prepared by standard procedures.

Ophthalmic Solutions:

20	<u>Example 1</u>	<u>mg/ml</u>
	active ingredient A or B	*
	Polyvinyl Alcohol	20.0
	Sodium phosphate Dibasic	1.2
	Sodium phosphate Monobasic	0.64
25	Eddetate Disodium	0.1
	Sodium Chloride	6.0
	Benzalkonium Chloride	0.1
	Purified Distilled Water QS. A.D.	1.0ml

	<u>Example 2</u>	<u>mg/ml</u>
	active ingredient A or B	*
	Hydroxypropyl Methylcellulose	5.0
	Boric acid	10.0
5	Benzalkonium Chloride	0.1
	Sodium Borate	0.7
	Eddate Disodium	0.1
	Sodium Chloride	3.0
	Purified Distilled Water QS.A.D.	1.0ml

10 Ophthalmic Ointment:

	<u>Example 3</u>	<u>Mg/g.</u>
	active ingredient A or B	*
	Purified Distilled Water	0.1ml
	Methyl Paraben	0.8
15	Propyl Paraben	0.1
	Hydrophilic Petrolatum QS. A.D.	1.0g

	<u>Example 4</u>	<u>Mg/g.</u>
	active ingredient A or B	*
	Chlorobutanol	5
20	Anhydous lanolin	10
	Mineral Oil	10
	White Petrolatum QS. A.D.	1.0g


Ophthalmic jel:

	<u>Example 5</u>	<u>Mg/g.</u>
25	active ingredient A or B	*
	Hydroxypropyl Methylcellulose	40.0
	Boric Acid	10.0
	Benzalkonium Chloride	0.1
	Sodium Borate	0.7
30	Eddate Disodium	0.1
	Purified Distilled Water QS. A.D.	1.0ml





CLAIMS for designated countries other than Austria

1. A topical ophthalmologically acceptable composition for reducing and controlling the elevated intraocular pressure associated with glaucoma which comprises an intraocular pressure reducing effective amount of a pharmaceutically acceptable angiotensin converting enzyme inhibitor, in combination with an ophthalmologically acceptable carrier for topical use.

10 2. The composition defined in claim 1 wherein said ACE inhibitor is a compound having the structural formula



wherein A is



15 R₂ is alkyl having from 1 to 6 carbon atoms, benzyl, benzylthio, benzyloxy, phenylthio or phenoxy;

R₁, R₃, R₄, and R₆ are the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms;

20 R₅ is hydrogen, alkyl having from 1 to 6 carbon atoms or amino alkyl having from 1 to 6 carbon atoms;

- 14 -

p is 0, 1 or 2;
 q is 0, 1 or 2, provided that the sum of p and
 q is 1 or 2 and that p is not 0 in formula 2;
 r is 1 or 2; and the pharmaceutically acceptable
 salts thereof.



5 3. The composition of claim 2, wherein in formula I
 R₁ and/or R₄ and/or R₆ is hydrogen and/or R₂ is benzyl
 and/or R₅ is methyl.


10 4. The composition of claim 2 or 3, wherein in
 formula I p and/or q and/or r is 1.

5 5. The composition of any one of claims 2 to 4 wherein
 in formula I A is the group X, Y or Z.

6 6. The composition of any one of claims 2 to 5,
 wherein said ACE inhibitor is


15





7. The composition according to any one of claims
2 to 6, wherein R_3 is hydrogen or ethyl.

8. The composition defined in claim 1, wherein said
5 ACE inhibitor is




9. Composition as defined in any one of claims
1 to 8 in the form of a dosage unit.


10. Use of a composition as defined in any one of
claims 1 to 9 for reducing and controlling the elevated
intraocular pressure associated with glaucoma.

CLAIMS for Austria

1. Process for the preparation of a topical ophthalmologically acceptable composition for reducing and controlling the elevated intraocular pressure associated with glaucoma, characterized in that an intraocular pressure reducing effective amount of a pharmaceutically acceptable angiotensin converting enzyme inhibitor is admixed with an ophthalmologically acceptable carrier for topical use.
- 10 2. Process according to claim 1, characterized in that said ACE inhibitor is a compound having the structural formula



wherein A is



R_2 is alkyl having from 1 to 6 carbon atoms, benzyl, benzylthio, benzyloxy, phenylthio or phenoxy;

20 R_1 , R_3 , R_4 , and R_6 are the same or different and are hydrogen or alkyl having from 1 to 6 carbon atoms;

R_5 is hydrogen, alkyl having from 1 to 6 carbon atoms or amino alkyl having from 1 to 6 carbon atoms;

p is 0, 1 or 2;

q is 0, 1 or 2, provided that the sum of p and

q is 1 or 2 and that p is not 0 in formula Z;

r is 1 or 2; and the pharmaceutically acceptable




5 salts and thereof.

3. Process according to claim 1, characterized in that
in formula I R₁ and/or R₄ and/or R₆ is hydrogen and/or
R₂ is benzyl and/or R₅ is methyl.

4. Process according to claim 2 or 3, characterized in
10 that in formula I p and/or q and/or r is 1.

5. Process according to any one of claims 2 to 4,
characterized in that in formula I A is the group X,
Y or Z.

15 6. Process according to any one of claims 2 to 5,
characterized in that said ACE inhibitor is




- 18 -

7. Process according to any one of claims 2 to 6,
characterized in that R_3 is hydrogen or ethyl.

8. Process according to claim 1, characterized in that
said ACE inhibitor is

5



9. Process according to any one of claims 1 to 8,
characterized in that the composition is brought into
the form of a dosage unit.

THIS PAGE BLANK (USPTO)